FDA approves teplizumab: a milestone in type 1 diabetes. PMID: 36436528 Teplizumab therapy for type 1 diabetes. PMID: 20095914 Antibodies to watch in 2023. PMID: 36472472 Antibodies to watch in 2020. PMID: 31847708 Teplizumab approval for type 1 diabetes in the USA. PMID: 36623521 Tepl...
FDA approves teplizumab: a milestone in type 1 diabetes. PMID: 36436528 Teplizumab therapy for type 1 diabetes. PMID: 20095914 Antibodies to watch in 2023. PMID: 36472472 Antibodies to watch in 2020. PMID: 31847708 Teplizumab approval for type 1 diabetes in the USA. PMID: 36623521 Tepl...
The recent FDA approval of teplizumab to delay the onset of T1D marks an impressive milestone in diabetes research and in clinical care. Nevertheless, an intensive scientific effort is still required to develop a sustainable method of screening children and identifying which children are most ...
The FDA indicated something was not well with Provention Bio's filing for type 1 diabetes therapy teplizumab in April when it delayed its review. Now, the agency has rejected the application entirely, sending the company's shares into a steep slide. The
FDA approves teplizumab: a milestone in type 1 diabetes. PMID: 36436528 Teplizumab therapy for type 1 diabetes. PMID: 20095914 Antibodies to watch in 2023. PMID: 36472472 Antibodies to watch in 2020. PMID: 31847708 Teplizumab approval for type 1 diabetes in the USA. PMID: 36623521 ...
Etanercept's therapeutic efficacy against many autoimmune diseases, including RA, juvenile idiopathic arthritis, psoriasis, ankylosing spondylitis, and IBD, has led to the subsequent approval of at least 5 additional TNF inhibitors by the FDA. However, 20–30% of patients either do not respond to ...